Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evotec Will Manage Malaria Compounds

by Michael McCoy
August 25, 2014 | A version of this story appeared in Volume 92, Issue 34

The drug discovery services firm Evotec will manage collections of pharmaceutically active compounds for two initiatives by the nonprofit Medicines for Malaria Venture. Evotec’s U.S. compound management facilities will house the so-called Malaria Box, which contains 400 molecules active against blood-stage Plasmodium falciparum malaria. To date, MMV says, more than 160 of the boxes have been dispatched to researchers in 27 countries. Evotec will also manage the “Pathogen Box,” a new collection of molecules for neglected diseases that MMV will have ready for distribution by the end of next year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.